by Vico Therapeutics | Feb 28, 2021 | Rare Disease day
As a friend of Rare Disease Day and to show our support in their continuous quest to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives, VICO Therapeutics together with BioPartner Leiden lit up...
by Vico Therapeutics | Feb 10, 2021 | Press Release
Leiden, The Netherlands, 10 February 2021 – Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted...
by Vico Therapeutics | Oct 1, 2020 | Press Release
Sandbrink, M.D., Ph.D. is a highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Topas, Bayer and Schering. Hinsby, Ph.D. is a seasoned life science entrepreneur and a co-founder and former...
by Vico Therapeutics | Jul 29, 2020 | Press Release
AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease Other early discovery stage RNA editing platform focuses on RETT syndrome Funding led by LSP, co-led by Kurma Partners, supported by Pontifax, Droia...